Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anne Barnes

Nurse Practitioner, Family Cheyenne, WY Nurse Practitioner

NPI 1649897406 CMS profile 10448550

4003 Rawlins St Ste A, Cheyenne, WY 82001

Open in the dashboard

General payments

$3,995

147 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anne Barnes of Cheyenne, WY is reported in the CMS Open Payments database as having received $3,995 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,373 58
2024 General $816 32
2023 General $21 1
2022 General $454 24
2021 General $1,331 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anne Barnes
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Anne Barnes were reported at $1,373. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Anne Barnes Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,331 $124 $35–$379 $132
2022 $454 $141 $44–$430 $149
2023 $21 $154 $49–$476 $160
2024 $816 $165 $51–$504 $164
2025 $1,373 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $810 2 payments
  2. Janssen Biotech, Inc. $421 10 payments
  3. AbbVie, Inc. $413 26 payments
  4. Regeneron Healthcare Solutions, Inc. $298 14 payments
  5. Madrigal Pharmaceuticals $268 8 payments
  6. AstraZeneca Pharmaceuticals LP $235 13 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $220 8 payments
  8. Lilly USA, LLC $215 11 payments
  9. Genzyme Corporation $173 7 payments
  10. Merck Sharp & Dohme Corporation $148 8 payments
  11. Other $793 40 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,925 142 payments
  2. Consulting Fee $810 2 payments
  3. Education $260 3 payments
Products named General payments · program years 2021–2025
  1. GILENYA $405 1 payment
  2. MAYZENT $405 1 payment
  3. REZDIFFRA $246 7 payments
  4. TREMFYA $225 6 payments
  5. STELARA $195 4 payments
  6. DUPIXENT Immunology And Inflammation $195 10 payments
  7. LINZESS $164 9 payments
  8. DUPIXENT Immunology $150 6 payments
  9. RINVOQ $148 11 payments
  10. ENTYVIO $140 5 payments
  11. Other $2,296 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

208

Median for Nurse Practitioner: 389

Drug cost

$12,828

Median for Nurse Practitioner: $21,885

Branded share of claims

46.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 12 $9,917
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 11 $1,340
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 31 $486
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 21 $301
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $214
Pantoprazole Sodium Generic 34 $178
Omeprazole Generic 25 $158
Doxycycline Hyclate Generic 15 $120
Ondansetron Hcl Generic 37 $113

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$28,622

Medicare's payments for the services billed

Medicare patients

356

Average age 73

Services billed

529

210 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 44%
Diabetes 26%
Ischemic heart disease 22%
Atrial fibrillation 17%
Depression 17%
Chronic kidney disease 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $195
$195 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $103
  • GENZYME CORPORATION $64
$167 — —
ZEPOSIA
  • Celgene Corporation $69
$69 — —
LINZESS
  • AbbVie, Inc. $51
$51 12 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record